Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models
Abstract
Understanding the mechanisms of drug transfer across the human placenta is critical for evaluating foetal exposure and developmental safety. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), a novel class of antidiabetics, remain poorly characterized with respect to their placental transfer and potential effect on placental function. Here, we address this knowledge gap. We investigated placental transfer mechanisms of dapagliflozin (DAPA), empagliflozin (EMPA), ertugliflozin (ERTU) and canagliflozin (CANA) using term placentas and complementary in vitro assays. All SGLT2i crossed the barrier within four hours of perfusion at clinically relevant concentrations. DAPA, the smallest compound, showed the fastest transfer, whereas EMPA, the largest, was the slowest. The more lipophilic compounds, CANA and ERTU, accumulated strongly in placental tissue. Transport of all SGLT2i - especially EMPA and ERTU - increased with the addition of an ATP-synthesis inhibitor, indicating the influence of active efflux transporters. Additionally, transport was significantly enhanced under low-bovine serum albumin conditions, implicating protein binding as a key rate-limiting factor. During Transwell® permeability assays, all SGLT2i crossed the BeWo b30 cell layer that mimics early gestational cytotrophoblasts. BeWo cells exposed to SGLT2i showed no impairment in forskolin-induced differentiation, viability, or secretion of pregnancy-related hormones, but revealed increased glycolytic activity.…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.